Inhibitors of NMT: A New Class of Chemotherapeutic Drugs

Authors: Gagan Bajaj; Anuraag Shrivastav; Ponniah Selvakumar; Mohammed K. Pasha; Yanjie Lu; Jonathan R. Dimmock; Rajendra K. Sharma

Source: Drug Design Reviews - Online, Volume 1, Number 4, October 2004 , pp. 347-354(8)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Myristoyl-CoA:protein N-myristoyltransferase (NMT) is an enzyme that catalyzes the attachment of myristate to the N-terminus of a number of cellular proteins of signal transduction pathways which may be involved in oncogenesis, in secondary cellular signaling and in infectivity of retroviruses. NMT expression and activity have been found to be elevated in cancers of the stomach, colon and gallbladder as well as in some leukemia cell lines. NMT is proposed as a novel molecular target for anticancer drug design. There is a rapidly expanding body of synthetic chemical and endogenous NMT inhibitors and this review discusses the design and characterization of some inhibitors from our laboratory.

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1567269043390744

Affiliations: 1: Department of Pathology, College of Medicine, and Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK, S7N 4H4, Canada.

Publication date: 2004-10-01